Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BXCL501 for Agitation Associated With Dementia
NCT05276830Phase 2Terminated
- Sponsor
- BioXcel Therapeutics, Inc.
- Start
- Feb 2022
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dexmedetomidine in agitation, sponsored by BioXcel Therapeutics, Inc.. Started Feb 2022; status: terminated.
02
Drugs
dexmedetomidine
03
Conditions
agitation
Beyond the preview
Go deeper on NCT05276830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05276830.